Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Illness | 7 | 2022 | 714 | 2.500 |
Why?
|
| Immunotherapy, Adoptive | 8 | 2023 | 1763 | 2.100 |
Why?
|
| Intensive Care Units | 10 | 2022 | 717 | 2.000 |
Why?
|
| Critical Care | 5 | 2020 | 770 | 1.210 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2022 | 113 | 0.900 |
Why?
|
| Hematologic Neoplasms | 4 | 2023 | 1870 | 0.880 |
Why?
|
| Mindfulness | 1 | 2022 | 58 | 0.810 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2021 | 35 | 0.780 |
Why?
|
| Immunotherapy | 4 | 2021 | 3341 | 0.740 |
Why?
|
| Myasthenia Gravis | 1 | 2021 | 99 | 0.730 |
Why?
|
| Cardiotoxicity | 1 | 2020 | 155 | 0.700 |
Why?
|
| Burnout, Professional | 1 | 2022 | 205 | 0.680 |
Why?
|
| Biological Products | 1 | 2022 | 274 | 0.650 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 598 | 0.630 |
Why?
|
| Neoplasms | 9 | 2023 | 15193 | 0.610 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 1039 | 0.480 |
Why?
|
| Lymphocytes | 1 | 2019 | 1234 | 0.470 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 884 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1303 | 0.400 |
Why?
|
| Referral and Consultation | 1 | 2016 | 899 | 0.390 |
Why?
|
| Legal Guardians | 1 | 2010 | 12 | 0.380 |
Why?
|
| Euthanasia, Passive | 1 | 2010 | 13 | 0.370 |
Why?
|
| Shock, Septic | 2 | 2022 | 181 | 0.360 |
Why?
|
| Life Support Care | 1 | 2010 | 50 | 0.360 |
Why?
|
| Cell- and Tissue-Based Therapy | 3 | 2023 | 406 | 0.360 |
Why?
|
| Brachytherapy | 4 | 2020 | 977 | 0.350 |
Why?
|
| Professional-Family Relations | 1 | 2010 | 134 | 0.340 |
Why?
|
| Physician's Role | 1 | 2010 | 238 | 0.310 |
Why?
|
| Sepsis | 2 | 2022 | 652 | 0.280 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2023 | 1146 | 0.270 |
Why?
|
| Palliative Care | 2 | 2015 | 2037 | 0.270 |
Why?
|
| Humans | 35 | 2023 | 261506 | 0.270 |
Why?
|
| Length of Stay | 3 | 2020 | 1900 | 0.230 |
Why?
|
| Retrospective Studies | 11 | 2022 | 37905 | 0.220 |
Why?
|
| Antidotes | 1 | 2022 | 28 | 0.220 |
Why?
|
| Decision Making | 1 | 2010 | 1287 | 0.210 |
Why?
|
| Consensus | 3 | 2023 | 978 | 0.210 |
Why?
|
| Patient Acuity | 1 | 2022 | 72 | 0.210 |
Why?
|
| Adult | 17 | 2023 | 77950 | 0.200 |
Why?
|
| Unilateral Breast Neoplasms | 1 | 2020 | 14 | 0.190 |
Why?
|
| Conservative Treatment | 1 | 2020 | 58 | 0.190 |
Why?
|
| Transfusion Reaction | 1 | 2021 | 102 | 0.190 |
Why?
|
| Salvage Therapy | 2 | 2020 | 2054 | 0.170 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2023 | 318 | 0.170 |
Why?
|
| Syndrome | 2 | 2019 | 1351 | 0.160 |
Why?
|
| Decision Trees | 1 | 2018 | 178 | 0.160 |
Why?
|
| Heart Arrest | 1 | 2023 | 358 | 0.160 |
Why?
|
| Middle Aged | 16 | 2023 | 86204 | 0.160 |
Why?
|
| Survival Rate | 8 | 2020 | 12221 | 0.150 |
Why?
|
| Comorbidity | 2 | 2022 | 2352 | 0.150 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 66 | 0.150 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 581 | 0.140 |
Why?
|
| Bronchial Fistula | 1 | 2016 | 37 | 0.140 |
Why?
|
| Mediastinal Diseases | 1 | 2016 | 56 | 0.140 |
Why?
|
| Aged | 12 | 2022 | 70117 | 0.140 |
Why?
|
| Ventilator Weaning | 1 | 2015 | 32 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2020 | 9244 | 0.140 |
Why?
|
| Iodine Radioisotopes | 2 | 2015 | 371 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2022 | 2803 | 0.130 |
Why?
|
| Mastectomy | 2 | 2020 | 1534 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2016 | 137 | 0.130 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 167 | 0.130 |
Why?
|
| Male | 14 | 2023 | 123000 | 0.130 |
Why?
|
| Female | 16 | 2023 | 141928 | 0.120 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2014 | 44 | 0.120 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2014 | 82 | 0.120 |
Why?
|
| United States | 2 | 2022 | 15433 | 0.120 |
Why?
|
| Patient Preference | 1 | 2015 | 218 | 0.110 |
Why?
|
| Prostatic Neoplasms | 3 | 2015 | 5767 | 0.110 |
Why?
|
| Tracheostomy | 1 | 2015 | 243 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2020 | 6869 | 0.110 |
Why?
|
| Cytokines | 2 | 2019 | 2809 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 1350 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 577 | 0.100 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 29902 | 0.100 |
Why?
|
| Cystic Fibrosis | 1 | 2014 | 264 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 1664 | 0.100 |
Why?
|
| Intensive Care, Neonatal | 1 | 2010 | 53 | 0.100 |
Why?
|
| Terminal Care | 1 | 2015 | 447 | 0.090 |
Why?
|
| Uveal Neoplasms | 1 | 2012 | 176 | 0.090 |
Why?
|
| Prognosis | 5 | 2022 | 21713 | 0.090 |
Why?
|
| Heart Failure | 1 | 2023 | 2516 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 2195 | 0.080 |
Why?
|
| Treatment Outcome | 7 | 2020 | 32848 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 4367 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2403 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 5687 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 6550 | 0.080 |
Why?
|
| Phyllodes Tumor | 1 | 2007 | 62 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 945 | 0.070 |
Why?
|
| Quality of Life | 1 | 2020 | 4532 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2014 | 1411 | 0.070 |
Why?
|
| Graft Survival | 1 | 2010 | 1062 | 0.070 |
Why?
|
| Emotions | 1 | 2010 | 562 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2010 | 611 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2010 | 769 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 764 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2010 | 834 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2014 | 10035 | 0.060 |
Why?
|
| Patient Discharge | 2 | 2023 | 661 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2010 | 755 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2015 | 495 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 1375 | 0.060 |
Why?
|
| Age Distribution | 2 | 2015 | 698 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2022 | 1274 | 0.060 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 1216 | 0.060 |
Why?
|
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 9 | 0.050 |
Why?
|
| Spain | 2 | 2012 | 113 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2022 | 305 | 0.050 |
Why?
|
| Mastectomy, Segmental | 2 | 2020 | 1026 | 0.050 |
Why?
|
| Cause of Death | 1 | 2022 | 752 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 485 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 649 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 577 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 827 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 750 | 0.040 |
Why?
|
| Age Factors | 2 | 2021 | 5377 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 4320 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2021 | 649 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 14889 | 0.040 |
Why?
|
| New York | 1 | 2015 | 104 | 0.030 |
Why?
|
| Fistula | 1 | 2016 | 76 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2015 | 70 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2015 | 79 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8865 | 0.030 |
Why?
|
| France | 1 | 2014 | 108 | 0.030 |
Why?
|
| Iridium Radioisotopes | 1 | 2014 | 56 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2010 | 15694 | 0.030 |
Why?
|
| Time Factors | 3 | 2015 | 12926 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 829 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2022 | 1423 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2014 | 12873 | 0.030 |
Why?
|
| Brain Diseases | 1 | 2017 | 403 | 0.030 |
Why?
|
| Adolescent | 3 | 2023 | 31252 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 2218 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 3441 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 6207 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2012 | 209 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 1323 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1249 | 0.020 |
Why?
|
| Mexico | 1 | 2010 | 259 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 2014 | 359 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 192 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2014 | 902 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 1546 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 10001 | 0.020 |
Why?
|
| Axilla | 1 | 2010 | 902 | 0.020 |
Why?
|
| Gestational Age | 1 | 2010 | 1069 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 2139 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 13658 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 3842 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 3260 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 1987 | 0.020 |
Why?
|
| Premature Birth | 1 | 2010 | 407 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2010 | 787 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 2422 | 0.020 |
Why?
|
| Child | 2 | 2021 | 29154 | 0.020 |
Why?
|
| Risk Factors | 2 | 2012 | 17523 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 2843 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2007 | 2307 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2010 | 1415 | 0.010 |
Why?
|
| Young Adult | 1 | 2021 | 21445 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 2231 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 2992 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 4988 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2012 | 9180 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 4844 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 7551 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 8223 | 0.010 |
Why?
|
| Pregnancy | 1 | 2010 | 7573 | 0.010 |
Why?
|